A 230 Kb probe covering the TP53(17p13.1) gene region is labeled with a green dye, and A 600 Kb probe covering the D13S319(13q14.2) gene region is labeled with an orange dye.

Detects TP53 deletions and D13S319/13q14 deletions in chronic lymphocytic leukemia for risk stratification and treatment decisions. TP53 alterations indicate high-risk disease with chemotherapy resistance, while D13S319 deletions are associated with favorable outcomes. Aids in identifying CLL patients eligible for targeted therapies like venetoclax.